Wielandt Ana María, Zárate Alejandro J, Hurtado Claudia, Orellana Paulina, Alvarez Karin, Pinto Eliana, Contreras Luis, Corvalán Alejandro, Kronberg Udo, López-Köstner Francisco
Unidad de Coloproctología, Laboratorio de Oncología y Genética Molecular, Chile.
Rev Med Chil. 2012 Sep;140(9):1132-9. doi: 10.4067/S0034-98872012000900005.
Selection of patients with Lynch Syndrome (LS) for a genetic study involves the application of clinical criteria. To increase the rate of identification of mutations, the use of molecular studies as Microsatellite Instability (MSI) and Immunohistochemistry (IHC) in the tumor has been proposed.
To demonstrate the usefulness of MSI and IHC in the detection of mutations in patients with LS.
From our Familial Colorectal Cancer Registry, families suspected of LS were selected according to Amsterdam or Bethesda clinical criteria. Screening of germline mutations of MLH1, MSH2 and MSH6 genes was performed. In addition, analysis of MSI and IHC were performed in colorectal tumors.
A total of 35 families were studied (19 met Amsterdam and 16 met Bethesda criteria). Twenty one families harbored a germline alteration in MLH1, MSH2 or MSH6 (18 Amsterdam and 3 Bethesda). In these families, eighteen different alterations were found, 15 of which were mutations and 3 corresponded to variants of uncertain pathogenicity. On the other hand, 80% of the tumors showed positive microsatellite instability (27 MSI-high and 1 MSI-low), and immunohistochemical testing showed that 77% of tumors had the loss of a protein. Correlation between results of tumor molecular studies and the finding of germline nucleotide change showed that IHC and MSI predicted mutations in 81 and 100% of patients, respectively.
MSI and IHC can efficiently select patients with a high probability of carrying a mutation in DNA repair genes.
选择林奇综合征(LS)患者进行基因研究需要应用临床标准。为了提高突变识别率,有人提出在肿瘤中使用微卫星不稳定性(MSI)和免疫组织化学(IHC)等分子研究方法。
证明MSI和IHC在检测LS患者突变中的有用性。
从我们的家族性结直肠癌登记处,根据阿姆斯特丹或贝塞斯达临床标准选择疑似LS的家族。对MLH1、MSH2和MSH6基因的种系突变进行筛查。此外,对结直肠癌肿瘤进行MSI和IHC分析。
共研究了35个家族(19个符合阿姆斯特丹标准,16个符合贝塞斯达标准)。21个家族在MLH1、MSH2或MSH6中存在种系改变(18个符合阿姆斯特丹标准,3个符合贝塞斯达标准)。在这些家族中,发现了18种不同的改变,其中15种是突变,3种对应于致病性不确定的变异。另一方面,80%的肿瘤显示微卫星不稳定性阳性(27个高度微卫星不稳定和1个低度微卫星不稳定),免疫组织化学检测显示77%的肿瘤存在一种蛋白质缺失。肿瘤分子研究结果与种系核苷酸变化发现之间的相关性表明,IHC和MSI分别在81%和100%的患者中预测了突变。
MSI和IHC可以有效地选择携带DNA修复基因突变可能性高的患者。